Penumbra (NYSE: PEN) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Penumbra to similar businesses based on the strength of its institutional ownership, risk, earnings, dividends, profitability, valuation and analyst recommendations.
This table compares Penumbra and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Penumbra and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Penumbra||$333.76 million||$4.65 million||-12,300.00|
|Penumbra Competitors||$1.54 billion||$111.80 million||-144.37|
Penumbra’s rivals have higher revenue and earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
73.4% of Penumbra shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 13.5% of Penumbra shares are owned by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Penumbra and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Penumbra currently has a consensus price target of $130.75, suggesting a potential upside of 6.30%. As a group, “Surgical & medical instruments” companies have a potential upside of 9.78%. Given Penumbra’s rivals higher probable upside, analysts plainly believe Penumbra has less favorable growth aspects than its rivals.
Risk & Volatility
Penumbra has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Penumbra’s rivals have a beta of 0.80, indicating that their average stock price is 20% less volatile than the S&P 500.
Penumbra rivals beat Penumbra on 7 of the 13 factors compared.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.